Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App





Thermo Fisher’s OmniPath COVID-19 Total Antibody ELISA Test for SARS-CoV-2 Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 08 Oct 2020
Thermo Fisher Scientific Inc.’s (Waltham, MA, USA) OmniPath COVID-19 Total Antibody ELISA Test for SARS-CoV-2 has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA).

Thermo Fisher has developed the test in collaboration with WuXi Diagnostics and the Mayo Clinic. More...
The OmniPath COVID-19 Total Antibody ELISA Test is designed to detect immunoglobulin M, A, and G against SARS-CoV-2 in human serum. The assay uses a 96-well microplate and can be run either manually or with the fully automatic Dynex Agility ELISA system from Thermo Fisher.

According to the FDA, the OmniPath COVID-19 Total Antibody ELISA Test can be run in the automated way by any lab that is CLIA-certified to perform moderate-complexity tests. The test can be performed in either manual or automated formats by labs certified to perform high-complexity tests.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
New
Repetitive Pipette
VWR® Stepper Pro
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer

Early-stage invasive breast cancer is frequently managed with breast-conserving surgery followed by adjuvant radiation therapy, but the magnitude of benefit from radiation varies among patients.... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.